RRSO at age 45 years for BRIP1 PV carriers was more cost-effective (ICER, £12 119/QALY) with higher OC risk estimates (relative risk, 5.54).7 When incorporating PARP-i treatment for BRCA-altered advanced OC, risk-reducing operations were cost-effective (RRSO or RRM plus RRSO were cost-saving) compared with BC surveillance and medical prevention with increased costs and QALYs but reduced NMB. The gene discussed is BRIP1; the disease is breast cancer.